Abstract
The aim of this study is to investigate visfatin levels in both synovial fluid (SF) and plasma of patients with primary knee osteoarthritis (OA) and its relationship with biomarkers of cartilage degradation in SF. Thirty OA patients, 12 SF control, and 12 plasma control subjects were enrolled in this study. Visfatin levels in both SF and plasma were measured using enzyme-linked immunosorbent assay (ELISA). Degradation biomarkers of collagen II and aggrecan in SF were also measured. The radiographic grading of OA in the knee was performed by the Kellgren-Lawrence (KL) criteria. Compared to controls, OA patients had higher SF visfatin concentration (8.95 ± 2.5 vs. 4.48 ± 2.49 ng/ml, P < 0.001). SF visfatin levels in KL grade 4 were significantly elevated compared with those of KL grade 3 (10.57 ± 2.49 vs. 7.54 ± 1.5 ng/ml, P = 0.001). SF visfatin positively correlated with degradation biomarker of collagen II, CTX-II (r = 0.497, P = 0.005), and degradation biomarker of aggrecan, AGG1 (r = 0.451, P = 0.012) and AGG2 (r = 0.434, P = 0.017). These findings suggest that SF visfatin might involved in cartilage matrix degradation.
Similar content being viewed by others
References
Lorenz H, Richter W (2006) Osteoarthritis: cellular and molecular changes in degenerating cartilage. Prog Histochem Cytochem 40(3):135–163
Clockaerts S, Bastiaansen-Jenniskens YM, Runhaar J, Van Osch GJ, Van Offel JF, Verhaar JA et al (2010) The infrapatellar fat pad should be considered as an active osteoarthritic joint tissue: a narrative review. Osteoarthritis Cartilage. doi:10.1016/j.joca.2010.03.014
Felson DT, Zhang Y, Hannan MT, Naimark A, Weissman B, Aliabadi P et al (1997) Risk factors for incident radiographic knee osteoarthritis in the elderly: the Framingham Study. Arthritis Rheum 40(4):728–733
Marks R, Allegrante JP (2002) Body mass indices in patients with disabling hip osteoarthritis. Arthritis Res 4(2):112–116
Manek NJ, Hart D, Spector TD, MacGregor AJ (2003) The association of body mass index and osteoarthritis of the knee joint: an examination of genetic and environmental influences. Arthritis Rheum 48(4):1024–1029
Presle N, Pottie P, Dumond H, Guillaume C, Lapicque F, Pallu S et al (2006) Differential distribution of adipokines between serum and synovial fluid in patients with osteoarthritis. Contribution of joint tissues to their articular production. Osteoarthritis Cartilage 14(7):690–695
Ushiyama T, Chano T, Inoue K, Matsusue Y (2003) Cytokine production in the infrapatellar fat pad: another source of cytokines in knee synovial fluids. Ann Rheum Dis 62(2):108–112
Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89(6):2548–2556
Dumond H, Presle N, Terlain B, Mainard D, Loeuille D, Netter P et al (2003) Evidence for a key role of leptin in osteoarthritis. Arthritis Rheum 48(11):3118–3129
Ku JH, Lee CK, Joo BS, An BM, Choi SH, Wang TH et al (2009) Correlation of synovial fluid leptin concentrations with the severity of osteoarthritis. Clin Rheumatol 28(12):1431–1435
Schäffler A, Ehling A, Neumann E, Herfarth H, Tarner I, Schölmerich J et al (2003) Adipocytokines in synovial fluid. JAMA 290(13):1709–1710
Trujillo ME, Scherer PE (2005) Adiponectin–journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 257(2):167–175
Senolt L, Pavelka K, Housa D, Haluzik M (2006) Increased adiponectin is negatively linked to the local inflammatory process in patients with rheumatoid arthritis. Cytokine 35(5–6):247–252
Hao D, Li M, Wu Z, Duan Y, Li D, Qiu G (2010) Synovial fluid level of adiponectin correlated with levels of aggrecan degradation markers in osteoarthritis. Rheumatol Int. doi:10.1007/s00296-010-1516-0
Busso N, Karababa M, Nobile M, Rolaz A, Van Gool F, Galli M et al (2008) Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS One 3(5):e2267
Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K et al (2005) Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307(5708):426–430
Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ et al (2006) Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 91(1):295–299
Panidis D, Farmakiotis D, Rousso D, Katsikis I, Delkos D, Piouka A et al (2008) Plasma visfatin levels in normal weight women with polycystic ovary syndrome. Eur J Intern Med 19(6):406–412
Moschen AR, Geiger S, Gerner R, Tilg H (2009) Pre-B cell colony enhancing factor/NAMPT/visfatin and its role in inflammation-related bone disease. Mutat Res Fundam Mol Mech Mutagen. doi:10.1016/j.mrfmmm.2009.06.012
Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, Tilg H (2007) Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 178(3):1748–1758
Rho YH, Solus J, Sokka T, Oeser A, Chung CP, Gebretsadik T et al (2009) Adipocytokines are associated with radiographic joint damage in rheumatoid arthritis. Arthritis Rheum 60(7):1906–1914
Gosset M, Berenbaum F, Salvat C, Sautet A, Pigenet A, Tahiri K et al (2008) Crucial role of visfatin/pre-B cell colony-enhancing factor in matrix degradation and prostaglandin E2 synthesis in chondrocytes: possible influence on osteoarthritis. Arthritis Rheum 58(5):1399–1409
Kellgren JH, Lawrence JS (1957) Radiological assessment of osteo-arthrosis. Ann Rheum Dis 16(4):494–502
Wang B, Chen P, Jensen AC, Karsdal MA, Madsen SH, Sondergaard BC et al (2009) Suppression of MMP activity in bovine cartilage explants cultures has little if any effect on the release of aggrecanase-derived aggrecan fragments. BMC Res Notes. doi:10.1186/1756-0500-2-259
Chen WP, Bao JP, Feng J, Hu PF, Shi ZL and Wu LD (2010) Increased serum concentrations of visfatin and its production by different joint tissues in patients with osteoarthritis. Clin Chem Lab Med. doi:10.1515/cclm.2010.230
Toussirot E, Streit G, Wendling D (2007) The contribution of adipose tissue and adipokines to inflammation in joint diseases. Curr Med Chem 14(10):1095–1100
Brentano F, Schorr O, Ospelt C, Stanczyk J, Gay RE, Gay S et al (2007) Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum 56(9):2829–2839
Fraser A, Fearon U, Billinghurst RC, Ionescu M, Reece R, Barwick T et al (2003) Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation. Arthritis Rheum 48(11):3085–3095
Little CB, Meeker CT, Golub SB, Lawlor KE, Farmer PJ, Smith SM et al (2007) Blocking aggrecanase cleavage in the aggrecan interglobular domain abrogates cartilage erosion and promotes cartilage repair. J Clin Invest 117(6):1627–1636
Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I (1994) Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 14(2):1431–1437
Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD et al (2004) Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 113(9):1318–1327
Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M et al (2005) Hormonal regulation of the novel adipocytokine visfatin in 3T3–L1 adipocytes. J Endocrinol 185(3):R1–R8
Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M et al (2005) Interleukin-6 is a negative regulator of visfatin gene expression in 3T3–L1 adipocytes. Am J Physiol Endocrinol Metab 289(4):E586–E590
Bae SK, Kim SR, Kim JG, Kim JY, Koo TH, Jang HO et al (2006) Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1. FEBS Lett 580(17):4105–4113
McGlothlin JR, Gao L, Lavoie T, Simon BA, Easley RB, Ma SF et al (2005) Molecular cloning and characterization of canine pre-B-cell colony-enhancing factor. Biochem Genet 43(3–4):127–141
Luk T, Malam Z, Marshall JC (2008) Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J Leukoc Biol 83(4):804–816
Otero M, Lago R, Gomez R, Lago F, Dieguez C, Gomez-Reino JJ et al (2006) Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 65(9):1198–1201
Acknowledgments
The authors would like to thank Dr. Jin Lin, Jin Jin, and Xisheng Weng for their help in sample collections.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Duan, Y., Hao, D., Li, M. et al. Increased synovial fluid visfatin is positively linked to cartilage degradation biomarkers in osteoarthritis. Rheumatol Int 32, 985–990 (2012). https://doi.org/10.1007/s00296-010-1731-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-010-1731-8